Get the Stockscreener App
0.2878
3.12%
0.0087
Plus Therapeutics Inc stock is traded at $0.2878, with a volume of 20.49M.
It is up +3.12% in the last 24 hours and down -54.83% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$0.2791
Open:
$0.283
24h Volume:
20.49M
Relative Volume:
2.68
Market Cap:
$39.97M
Revenue:
-
Net Income/Loss:
$-12.89M
P/E Ratio:
-0.1138
EPS:
-2.53
Net Cash Flow:
$-11.95M
1W Performance:
-48.16%
1M Performance:
-54.83%
6M Performance:
-11.17%
1Y Performance:
-75.82%
1-Day Range:
$0.263
$0.2985
1-Week Range:
$0.2511
$0.513
52-Week Range:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.2878 | 38.77M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Plus Therapeutics completes underwritten public equity offering - TipRanks
Plus Therapeutics Signs Underwriting Agreement With Lake Street Capital Markets - TradingView — Track All Markets
Plus Therapeutics Inc enters underwriting agreement with Lake Street Capital Markets, LLCSEC filing - marketscreener.com
Plus Therapeutics IncOn Jan 13, Co Enters Underwriting Agreement With Lake Street Capital Markets, LlcSEC Filing - TradingView — Track All Markets
Should you avoid Plus Therapeutics Inc stock right nowPortfolio Profit Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Whale Trades: Is UONE stock suitable for long term investingJuly 2025 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
Analyst Downgrade: Is UDR Inc in accumulation or distribution phaseJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering - Sahm
Plus Therapeutics prices $15 million public offering at $0.38 per unit - Investing.com Nigeria
Plus Therapeutics Spurs After-Hours Biotech Rally; Connect Biopharma And Elutia Also Advance - Nasdaq
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - MSN
Plus Therapeutics stock plunges after pricing $15M units offering - MSN
Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges - Benzinga
PSTV Plunges On $15 Mln Upsized Offering - Nasdaq
Plus Therapeutics (PSTV) Shares Plummet After $15M Unit Offering - GuruFocus
Plus Therapeutics (PSTV) Launches $15M Public Offering - GuruFocus
Plus Therapeutics announces pricing of upsized $15 million public offering - marketscreener.com
Dow Update: Can Plus Therapeutics Inc reach all time highs this yearQuarterly Trade Summary & AI Enhanced Execution Alerts - baoquankhu1.vn
Sell Signal: Will Plus Therapeutics Inc stock benefit from upcoming earnings reportsJuly 2025 Recap & High Yield Stock Recommendations - moha.gov.vn
Sify Technologies, Boot Barn Holdings And 3 Stocks To Watch Heading Into Monday - Benzinga
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - sharewise.com
How Plus Therapeutics Inc. (XMP0) stock expands through international marketsQuarterly Portfolio Review & Risk Managed Trade Strategies - ulpravda.ru
HOKA Buying Guide: Can Plus Therapeutics Inc. stock continue upward trend - ulpravda.ru
Plus Therapeutics completes FDA meeting on REYOBIQ trial strategy By Investing.com - Investing.com Nigeria
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases - Sahm
Why Plus Therapeutics Inc. stock is a value investor pickStop Loss & AI Based Buy/Sell Signal Reports - ulpravda.ru
Is Plus Therapeutics Inc. stock cheap at current valuationWeekly Profit Summary & Weekly Return Optimization Plans - ulpravda.ru
Is Plus Therapeutics Inc. stock a buy in volatile markets2025 Key Lessons & Advanced Swing Trade Entry Plans - ulpravda.ru
Can Plus Therapeutics Inc. stock continue upward trendEarnings Growth Report & Daily Price Action Insights - ulpravda.ru
Plus Therapeutics stock falls after FDA meeting on REYOBIQ trial By Investing.com - Investing.com Australia
Plus Therapeutics stock falls after FDA meeting on REYOBIQ trial - Investing.com
Plus Therapeutics Stock (PSTV) Opinions on FDA Meeting for REYOBIQ™ Approval - Quiver Quantitative
PSTV: Today's Analyst Ratings Maintains 'Buy' with Consistent Pr - GuruFocus
Plus Therapeutics' (PSTV) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Plus Therapeutics (PSTV) Advances with FDA on REYOBIQ Trial for Leptomeningeal Metastases - GuruFocus
Plus Therapeutics announces read out of Type B meeting with the FDA - MarketScreener
Plus Therapeutics completes FDA meeting on REYOBIQ trial strategy - Investing.com
Plus Therapeutics, Inc. Completes FDA Type B Meeting on REYOBIQ Pivotal Trial Strategy for Leptomeningeal Metastases - Quiver Quantitative
Plus Therapeutics Announces Read Out of Type B Meeting with - GlobeNewswire
How Plus Therapeutics Inc. stock reacts to job market dataSector Performance Drivers & Minimal Capital Trading - ulpravda.ru
2026 world cup points table rankings: How Plus Therapeutics Inc. stock responds to policy changes2026 world cup usa national team round of 32 star players set piece tactics knockout prediction tactical review - ulpravda.ru
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN
Analyst Downgrade: How Plus Therapeutics Inc XMP0 stock expands through international marketsMarket Risk Summary & Accurate Intraday Trade Tips - moha.gov.vn
Guidance Update: Can Plus Therapeutics Inc XMP0 stock attract analyst upgradesJuly 2025 Setups & Safe Entry Momentum Tips - moha.gov.vn
Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
How Plus Therapeutics Inc. stock responds to policy changes2025 Market Overview & Safe Entry Momentum Tips - ulpravda.ru
Is Plus Therapeutics Inc. (XMP0) stock a top hedge fund pick2025 Momentum Check & Real-Time Stock Price Movement Reports - Улправда
Can Plus Therapeutics Inc. (XMP0) stock ride next bull market cycleQuarterly Trade Summary & Weekly Breakout Stock Alerts - Улправда
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Plus Therapeutics Inc Stock (PSTV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
38,323 |
0 |
106,461 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Nov 04 '25 |
Buy |
0.51 |
20,000 |
10,200 |
68,138 |
| HEDRICK MARC H | Chief Executive Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
159,681 |
0 |
180,106 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
38,323 |
0 |
48,138 |
| Lenk Robert P | Director |
Aug 22 '25 |
Buy |
0.49 |
110,000 |
53,779 |
139,327 |
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):